No Data
No Data
No Data
No Data
No Data
Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors To...
Stockhouse Apr 14 11:00 ET
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
OcugenApr 12 00:00 ET
Ocugen Says EU Backs a U.S. Trial for Gene Therapy
Seeking AlphaApr 10 10:20 ET
Express News | Ocugen Disclosed Positive Scientific Advice From The European Medicines Agency Related To The Approval Pathway For Ocu400—Modifier Gene Therapy For Broad Retinitis Pigmentosa Indication
Moomoo 24/7Apr 10 07:05 ET
Ocugen, Inc. Announces Positive Scientific Advice From the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
OcugenApr 10 00:00 ET
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA)
TipRanksApr 9 08:10 ET
The Real Wojak : Just sold the other half of my shares at $1.85 and $1.86 thank you very much :)
The Real Wojak : Will re-load in the $1.60’s
The Real Wojak : Impressive, still not chasing it though. Ready for a pullback next week otherwise will pass
No Data
No Data